Pamela Hershberger, Ph.D.
Health Research Incorporated, Roswell Park Cancer Institute Division
Development of Tumor Targeted Nanoparticles to Combat EGFR TKI Resistance
Lung Cancer Discovery Award
EGFR mutant lung cancers are diagnosed in nearly 250,000 individuals worldwide each year. These cancers are treated using drugs called EGFR tyrosine kinase inhibitors (EGFR TKIs). Although initially effective, almost all tumors stop responding to treatment in 1.5 years. In an increasing number of cases, EGFR TKIs stop working because tumors undergo a process termed the epithelial-mesenchymal transition (EMT). Our studies test a novel approach to reverse EMT and restore tumor sensitivity to EGFR TKIs. Our approach uses a protective shell or nanoparticle (NP) to deliver vitamin D (VD) and a drug called CTA091 to EGFR mutant tumors. Once inside tumor cells, VD reverses EMT. CTA091 prevents tumors from destroying VD, thus sustaining therapeutic benefit. The proposed studies will establish the safety and activity of our NP in combination with EGFR TKIs in lung tumor models, including patient avatars. Positive results will provide a solution to the problem of EMT-mediated drug resistance.
Sign up for the latest lung health news sent right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.